China’s Innovent Biologics has expanded its international marketing network by agreeing a licensing deal for its Byvasda (bevacizumab) biosimilar version of Avastin in Indonesia with local firm PT Etana Biotechnologies Indonesia.
In exchange for Etana gaining development and commercialization rights in Indonesia to Byvasda, Innovent will receive development and commercialization milestone...






